MiNA Therapeutics is a clinical stage biotechnology company pioneering transcriptional gene activation using small activating RNA (saRNA).

saRNA design

Delivery

Gene activation

Protein production

saRNA provide a new way of stimulating a cell’s messenger RNA (mRNA) and protein production. saRNA therapeutics hold promise for many conditions and diseases that are untreatable with today’s conventional medicines.


Rational discovery engine

Harnessing a proprietary bioinformatics platform, MiNA is rapidly discovering and developing saRNA to selectively up-regulate protein expression.

Endogenous activation mechanism

saRNA recruit endogenous transcriptional complexes to a target gene, leading to increased expression of naturally processed mRNA that replicate full target gene functionality.

Persistent activation

Gene activation by saRNA is accompanied by epigenetic changes, resulting in prolonged protein upregulation lasting weeks.

Target flexibility

saRNA can upregulate nuclear factors, intra-cellular proteins and secreted proteins alike, in cases where genes are both naturally expressed or epigenetically silenced.

Clinical readiness

saRNA leverages decades of experience in the broader oligonucleotide field covering assay development, chemistry, manufacturing, formulation, clinical and regulatory.

Intellectual Property

MiNA has a strong IP position and is building a comprehensive patent portfolio. MiNA holds technology assignments and licenses from University of Texas Southwestern Medical Center, UCSF and Norwegian University of Science and Technology.